4 Psychedelics Companies Post Financial Results: Learn How Field Trip, Wesana, Braxia and Irwin Naturals Performed
Field Trip (NASDAQ: FTRP), Wesana (OTCQB: WSNAF), Braxia (OTC: BRAXF) and
Telehealth Market News: Braxia Scientific Enters Industry By Acquiring Ketamine Treatment Platform In Florida
A researcher and provider of ketamine-assisted treatments for mental health conditions, Braxia Scientific Corp.
Canadian Special Access Program Further Authorizes Novel Psychedelic Drugs For Emergency Treatments
For those unaware, Canada provides a legal way for patients presenting unresolved mental health issues to receive psychedelic-assisted treatment.
These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry
In the nascent industry of medical psychedelics, drug development is the name of the game.
This subset of biotech, poised to become a $100 billion industry according to Canaccord Genuity, bases its success on the regulation and approval of scheduled psychoactive substances for mental health and other health indications.
There Are Now 50 Psychedelics Companies Listed In The U.S. – Here They Are
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors.
New Study Suggests Ketamine Could Work Better Without Additional Antidepressants
Braxia Scientific Corp. (CSE: BRAX) (OTC: BRAXF) released results of a clinical study suggesting that ketamine could be as effective on its own in the treatment of depression as it is in combination with traditional antidepressants.
Braxia Scientific Launches Broad Criteria Trial On Psilocybin For Depression
Braxia Scientific Corp. (CSE: BRAX) (OTC: BRAXF), a Toronto-based psychedelics company, is launching a randomized clinical trial using psilocybin for adults with treatment-resistant depression.